Streetbeat News

Price Targets

MU

B of A Securities has maintained its Buy rating on Micron Technology and raised the price target from $110 to $125, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 4:00 pm

PL

Over the past three months, analysts have shared mixed opinions on Planet Labs (NYSE:PL), with ratings ranging from bullish to bearish. The average 12-month price target is $3.94, down 6.41% from the previous average. Analysts have adjusted their ratings and price targets in response to market conditions, with some maintaining their stance and others lowering their targets. Planet Labs has shown notable revenue growth but faces challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:00 pm

ECL

Analysts have varied opinions on Ecolab (NYSE:ECL), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 5.55% to $271.5. Ecolab's financials show strong net margins and ROE, but revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:00 pm

IONS

Ionis Pharmaceuticals (NASDAQ:IONS) has received mixed analyst ratings, with a recent average price target of $61.08, reflecting a 10.89% increase from the previous target. Analysts have varied in their ratings, with some raising their price targets and others maintaining or lowering them. Ionis is a leader in antisense technology, with a focus on cardiovascular, metabolic, neurological, and rare diseases. Despite positive revenue growth, the company faces challenges with below-average ROE and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:00 pm

META

B of A Securities has maintained its Buy rating on Meta Platforms and raised the price target from $563 to $630, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:58 pm

EVAX

HC Wainwright & Co. has reiterated its Buy rating for Evaxion Biotech (NASDAQ:EVAX) and maintained a price target of $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:55 pm

IVA

Stifel analyst Annabel Samimy maintains a Buy rating on Inventiva (NASDAQ:IVA) but lowers the price target from $25 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:53 pm

GWRE

Stifel analyst Parker Lane maintains a Buy rating on Guidewire Software (NYSE:GWRE) and raises the price target from $175 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:51 pm

EPRT

Stifel analyst Simon Yarmak maintains a Buy rating on Essential Props Realty (NYSE:EPRT) and raises the price target from $32 to $36.25.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:49 pm

ARGX

Guggenheim analyst Yatin Suneja has reiterated a Buy rating on argenx (NASDAQ:ARGX) and maintained a price target of $585.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 3:49 pm